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Introduction 
Development of vaccines for effective control of foodborne pathogens and 
infection represents an important development in reducing public health risk.  
Advancements in the area of biotechnology have increased innovative potential and 
allow new technologies to be used as a promising control strategy for alternatives to 
antibiotics.  We have been working to create a novel vaccine platform that incorporates 
a subunit/epitope sequence, common for all E. coli strains (broad spectrum), into an 
inactivated orally administered vaccine platform that protects against infection and 
disease by inducing mucosal immunity.  
 The mucous membranes constitute the major portal of entry for infectious agents 
and include membranes of the nasal, respiratory, gastrointestinal, and genitourinary 
tract; as well as the occular conjunctiva, the inner ear and the ducts of all exocrine 
glands.  Collectively they cover more than 400m
2 
in humans, compared to only 2m
2 
of 
skin, and serve as the first line of defense against infection at the entry points for a 
variety of pathogens (Ogra et al., 2001). The gastrointestinal system is the largest 
lymphoid organ in the body containing an estimated 70% to 80% of the body’s 
immunoglobulin–producing cells (Kaul 1999).  80% of all the activated B cells in the 
body are located at the mucosal tissues (Brandtzaeg et al., 1989) In fact the only way to 
contract an infection other than the mucosal portal of entry is through blood-borne 
vectors or damage to epithelial surfaces.  
Despite its important role, currently only a handful of vaccines specifically target 
this area of the immune system despite strong evidence that a robust mucosal response 
can effectively prevent systemic infections (Ogra et al., 2001). Increasing evidence has 
indicated that mucosal vaccination can induce both systemic and local mucosal 
immunity, while systemic immunization generally fails to elicit strong mucosal 
immunity (Valosky et al., 2005).  Also, the concept of a common mucosal immune 
system predicts that induction of immunity at one mucosal surface, such as the gut, can 
provide immunity at another mucosal surface, such as the lung (Cerkinsky et al., 1995) 
providing a necessary link for immunity transfer throughout mucosal surfaces. Mucosal 
immunity may prove to be the link in fighting a complex infection in which systemic 
and local immunity are necessary in preventing the spread and transmission of 
infectious disease and foodborne pathogens.    
Pathogenic E. coli infections, or colibacillosis, is one of the most prevalent 
diseases affecting the global swine industry (Fairbrother J. et al., 2005). Enterotoxigenic 
Escherichia coli (ETEC) is a major cause of illness and death in neonatal and recently 
weaned pigs in some cases young pigs can lose up to 40% of their body weight and in 
severe cases mortality can reach 100% (USDA 2002).  Colibacillosis not only has a 
direct economic impact on producers it also represents a potential human transmission 
route of foodborne illness.  Common treatment options often include incorporation of 
antibiotics to control and limit spread of the disease; however, the disease is becoming 
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increasingly more difficult to treat due to acquired antibiotic resistance.  Moreover, 
consumer pressure and changing government regulations may limit or omit the use of 
antibiotics necessitating the need for alternative intervention strategies.  
Our vaccine development, in which a single vaccine, can simultaneously and 
effectively control all or the majority of serotypes/strains that make up the 150-200 
serotypes that represent the E. coli family of pathogens (broad spectrum) and provide 
protection in multiple species (swine, poultry, bovine, fish, humans) potentially 
represents practical biotechnological progress as an alternative intervention strategy in 
controlling diseases and foodborne pathogens.  
 
Materials and methods 
Development of subunit orally administered inactive vaccine against E. 
coli spp. (Biotech Vac E. Coli) 
 Briefly vaccine construction was as follows: a synthetic, antigenic, epitope, 
genetic sequence common for E. coli spp. was inserted by direct ligation into a Bacillus 
subtilis expression plasmid.  The genetic sequence was put under the control of an IPTG 
inducible promoter present on the expression plasmid and inserted into the multiple 
cloning site of the plasmid for Open Reading Frame expression.  The modified 
expression plasmid was then transfected into E. coli TOPO 1 cells for confirmation of 
gene insert and multiplication of the plasmid.  The multiplied confirmed plasmid was 
then isolated, concentrated and transfected into the vector Bacillus subtilis 
VBTSLL11™, a proprietary Bacillus strain selected specifically for use in the Biotech 
Vac platform. Once plasmid insertion was confirmed by colony PCR, DNA sequencing 
was performed to confirm correct genetic sequence and protein expression was 
quantified by SDS-PAGE western blotting.  This newly constructed and verified 
Bacillus strain was used to manufacture the antigenic E. coli subunit.  The bacteria were 
grown under normal Bacillus culture conditions in Tryptic Soy Broth (TSB) at 37C, 
after 4 hours of growth the culture was induced with 1mM of Isopropyl β-D-1-
thiogalactopyranoside (IPTG) followed by an additional 5 hours of growth.  Once 
fermentation was complete the culture was inactivated and added to an encapsulation 
media for incorporation of the epitopes into micro-particles for oral delivery. Subunit 
concentration for each 2.0ml dose of vaccine is approximately 500ng.   
 
Challenge with Escherichia coli 
 Two wild-type field isolates (VBTEcoli1-2) of Enterotoxigenic E. coli (ETEC) 
originally isolated from swine farms in Argentina were grown individually to log phase, 
combined, serially diluted, and enumerated by spectrophotometric density and 
comparison to a previously generated standard curve.  
These strains were diluted to approximately 10
8
cfu/ml for challenge by oral 
gavage at a dose of 2.0ml/pig for 2 consecutive days. 
 
Vaccination study 1 
In the first challenge trial, two groups of 3 day old piglets at a commercial 
production farm were assigned to one of two experimental groups, the piglet and sows 
in these two groups were isolated from the rest of the commercial farm.  A non-treated 
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control group (n=13) that received 2.0ml of saline by oral gavage on days 3 and 14 of 
life or a treated group (n=12) that received 2.0ml of Biotech Vac E. coli vaccine by oral 
gavage on days 3 and 14 of life.  All piglets in both groups were challenge with 2.0ml of 
ETEC E. coli by oral gavage (challenge preparation described above) on days 17 and 18 
of life.  Piglets were observed for 1 week following challenge and presence or absence 
of diarrhea was recorded daily.  Additionally, individual weight gain was calculated. 
During the course of the experiment, neither the piglets nor the lactating sows received 
antibiotic treatment and antibiotics were not present in the commercial feed.  
 
Vaccination study 2 
In the second challenge trial, thirty 28 day old pigs from a commercial production 
farm were randomly assigned to either a non-treated control group or a Biotech Vac E. 
coli vaccine treated group (n=15/group), transferred to adjacent weaning boxes isolated 
from the rest of the commercial farm and allowed to acclimate for 5 days.  Following 
the acclimation period (day 33 of life), pigs were either given by oral gavage 2.0ml 
saline (control group) or 2.0ml Biotech Vac E.coli. and subsequently administered the 
same treatment 10 days (day 43 of life) following the first administration. Three and 
four days following the second treatment administration (day 44 & 47 of life), all pigs in 
both groups were challenged with 2.0ml of ETEC E. coli by oral gavage (challenge 
preparation described above).  Pigs in both groups were observed for 10 days following 
challenge and presence or absence and type of diarrhea was recorded daily. Pigs were 
fed standard commercial diets containing no antibiotics.   
 
Results 
Results from the 1
st
 challenge trial done in newborn piglets under standard 
commercial production conditions showed that on day 20 48 hours after trial 100% 
(13/13) of the piglets in the control non-treated group had developed clinical signs of 
diarrhea consistent with Colibacillosis with the diarrhea continuing for 72 hours. While 
the piglets that were vaccinated with Biotech Vac E. Coli, exhibited no clinical signs 
and did not develop diarrheas throughout the 1 week observation period.  Additionally, 
piglets in the Biotech Vac E. coli treated group had a slightly increased total weight gain 
and daily body weight gain when compared to the non-treated controls; 46.4kg vs 
45.6kg respectively (total weight gain) and 1.93kg vs 1.90kg respectively (daily body 
weight gain).  No mortality was observed in either experimental group. 
In the 2
nd
 challenge trial, conducted in weanling pigs, results demonstrated 
significant reductions in the percentage, severity and duration of ETEC associated 
diarrheas in the group vaccinated with Biotech Vac E. coli when compared to the non-
treated control group under standard commercial production conditions.  In the group 
treated with the vaccine 4 days after challenge 20% (3/15) of the pigs exhibited 
diarrheas lasting 1 day and 6.7% (1/15) of the pigs had mild diarrhea that lasted 3 days.  
Also, in the group receiving the vaccine, 1 pig exhibited severe diarrhea (perineal 
congestion) and ultimately was diagnosed with pneumonia.  While in the non-treated 
control group: 
 Day 3 post-challenge: 20% (2/15) of the pigs began with diarrhea.  
 Day 4 post-challenge: 73% (11/15) of the pigs were present with diarrhea ranging 
in severity and consistency. 
 Day 5 post-challenge: 73% (11/15) of the pigs were still present with diarrhea. 
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 Day 6 post-challenge: 20% (2/15) of the pigs continued to exhibit mild diarrhea.  
 No mortality was observed in either experimental group. 
 
Conclusions 
Results of 2 separate ETEC E. coli challenge trials in commercial newborn piglets 
and weanling pigs that received two doses of Biotech Vac E. coli demonstrated:  
significant reductions of clinical symptoms associated with E. coli, significant 
reductions in the severity of E. coli associated diarrheas and a reduction in time in 
which the clinical signs and diarrheas persisted.  These preliminary results suggest that 
our inactivated orally administered subunit vaccine platform offers a promising 
alternative for the control of infections and pathogens associated with foodborne 
diseases.   
 
References 
Fairbrother, J., Nadeau, E., and Gyles, C. 2005. “Escherichia coli in postweaning diarrhea in pigs: an 
update on bacterial types, pathogenesis, and prevention strategies.” Anim. Health Res. Rev. 6(1): 17-39. 
 
Brandtzaeg, P.; Halstensten, T.; Kett, K.; Krajci, P.; Kvale, D.; Rognum, T.O.;  Scott, H.; Sollid, L.M. 
Gastroenterology. 97, 1562. 1989. 
 
Cerkinsky C, Quiding M, Eriksson K, Nordstrom I, Lakew M, Weneras C, et al. Induction of specific 
immunity at mucosal surfaces: 371B:1409-16. 1995. 
 
Kaul R, Trabattoni D, Bwayo JJ, Arienti D, Zagliani A, Mwangi FM, Kariuki C, Ngugi EN, MacDonald 
KS, Ball TB, Clerici M, Plummer FA.HIV-1-specific mucosal IgA in a cohort of HIV-1-resistant Kenyan 
sex workers. AIDS.13(1):23-9. 1999. 
 
Ogra PL, Faden H, Welliver RC.Vaccination strategies for mucosal immune responses. Clin Microbiol 
Rev. 14(2):430-45. 2001. 
 
USDA. 2002. Pages 7–25 in Part II: Reference for Swine Health and Health Management in the United 
States, 2000. #355.0202. USDA:APHIS:VS, CEAH, Natl. Anim. Health Monitoring Sys., Ft. Collins, 
CO. 
 
Valosky J., Hishiki H., Zaoutis T.E., Coffin S.E.  Induction of mucosal B-cell memory by intranasal 
immunization of mice with respiratory syncytial virus. Clin Diagn Lab Immunol. 12(1):171-9. 2005. 
 
 
 
 
